The present study searched for a wide spectrum of features that might influence the survival of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. A total of 266 patients, who had received sunitinib, pazopanib, or sorafenib, were evaluated using multivariable analysis and 2 bootstrap procedures. The results indicate that Fuhrman grade and the neutrophil-to-lymphocyte ratio are, in addition to previously identified factors, independently associated with survival. Background: The present study investigated the various features that might influence the overall survival (OS) of patients with metastatic renal cell carcinoma (RCC) treated with first-line tyrosine kinase inhibitors (TKIs). Patients and Methods: A retrospective analysis was performed of consecutive patients with metastatic RCC, in whom treatment with a first-line TKI was initiated from January 2010 to December 2014, at the Department of Oncology, Military Institute of Medicine (Warsaw, Poland). Cox proportional hazards regression was used to construct a prognostic model that included independent factors for OS. We validated the model using 2 bootstrap procedures and calculation of the bias-corrected concordance index. Results: Of the 266 patients included in the study, 201, 45, and 20 received sunitinib, pazopanib, and sorafenib, respectively. The median OS for the whole cohort was 24.8 months (95% confidence interval, 20.2-29.4 months). Six factors were independently associated with poor survival: Eastern Cooperative Oncology Group performance status > 0 (P < .0001), Fuhrman grade 3 to 4 (P < .0001), hemoglobin less than the lower limit of normal (P < .0001), lactate dehydrogenase greater than the upper limit of normal (P ¼ .0011), neutrophil-to-lymphocyte ratio ! 4 (P < .0001), and > 2 metastatic sites (P ¼ .0012). The bias-corrected concordance index was 0.751. Conclusion: Fuhrman grade and neutrophil-to-lymphocyte ratio are potential factors that affect the survival of patients with metastatic RCC treated with first-line TKIs. The presented prognostic model demonstrated satisfactory performance but requires external validation with a larger data set.
Introduction
Renal cell carcinoma (RCC) is the most common type of kidney cancer. 1 The development of metastases is the major cause of tumorassociated death. Surgical resection of solitary or multiple metastases should be considered in selected patients, because it can prolong cancerspecific survival and overall survival (OS). 2 Most patients with metastatic disease, however, require systemic treatment, which is currently based on molecular targeted therapies. The current lack of factors able to predict the therapy-associated response and diversion of the natural disease course has made the survival prognosis essential in patient evaluation and further treatment. The prognostic models constructed for this purpose divide patients into 3 risk groups, depending on the number of factors influencing survival: Karnofsky or Eastern Cooperative Oncology Group performance status (PS) (Memorial Sloan from diagnosis to treatment (MSKCC, IMDC, and IKCWG models), interval from diagnosis to metastasis (French model), the number of metastatic sites (IKCWG and French models), liver metastasis (French model), previous immunotherapy (IKCWG model), hemoglobin level (MSKCC, IMDC, and IKCWG models), corrected or uncorrected serum calcium level (MSKCC, IMDC, and IKCWG models), neutrophil count (IMDC model), platelet count (IMDC model), serum lactate dehydrogenase (LDH) level (MSKCC and IKCWG models), white blood cell count (IKCWG model), and serum alkaline phosphatase level (IKCWG model). Patients in the favorable and intermediate risk groups will strongly benefit from tyrosine kinase inhibitors (TKIs), which have a leading role in first-line and subsequent therapies. [7] [8] [9] [10] Despite the high applicability of these models, a need for improved management remains for patients receiving TKIs. Thus, we retrospectively analyzed our patients' medical records and searched for clinical, pathologic, and radiologic features and laboratory results that might influence survival in this group of patients.
Patients and Methods

Patients
The present study included consecutive patients who had begun treatment with a first-line TKI from January 2010 to December 2014 at the Department of Oncology, Military Institute of Medicine (Warsaw, Poland). The inclusion criteria were as follows: (1) histologically confirmed metastatic RCC of any histopathologic subtype; (2) previous nephrectomy or nephron-sparing surgery; (3) no previous radiotherapy; (4) no other malignancies; and (5) no previous TKI therapy. Only those patients treated using standard schedules and receiving !1 dose of TKI were eligible. Those patients treated with immunotherapy before the initiation of a TKI (ie, TKI therapy was second-line systemic treatment) and/or who had initially undergone surgery for metastatic disease (ie, resection of pulmonary metastases) were also included. Patients who had received adjuvant therapy or an investigational agent (ie, dovitinib) or an investigational combination (ie, sunitinib plus enzastaurin) at any time after diagnosis were excluded.
The exact dates of deaths were obtained from the Polish National Health Fund database (available at: https://csm-swd.nfz.gov.pl/). All other information was gathered from the patients' individual medical records. The ethics committee of the Military Institute of Medicine, Warsaw approved the study.
Outcomes
Because of the retrospective nature of the study, a sample size calculation was not performed. The assessed outcome was OS, defined as the time from the initiation of first-line TKI treatment to death from any cause. The survival data were last updated on September 1, 2015. Patients still alive at that date or lost to followup were censored. The serum corrected calcium was calculated as follows: total serum calcium þ 0.8 Â [4 À serum albumin]. The neutrophil-to-lymphocyte ratio (NLR) was defined as the absolute neutrophil count divided by the absolute lymphocyte count. The platelet-to-lymphocyte ratio (PLR) was defined as the absolute platelet count divided by the absolute lymphocyte count.
Statistical Analysis
The variables measured on an ordinal or a continuous scale were converted to binary variables using predefined cut points. The Kaplan-Meier method was used to estimate the time-to-event curves and median values and 95% confidence intervals (CIs) for OS. The median follow-up time was calculated using the Schemper and Smith method. 11 On univariable analysis, the factors were assessed using the log-rank test; those that reached statistical significance were included in the multivariable analysis using the Cox proportional hazard regression. A stepwise forward procedure with a significance level of .05 for entering and removing variables was used to select the independent factors. The proportionality of hazards assumption was checked in a 2-step procedure. In the first step, a graphic assessment with plots of natural logarithm (ln) (Àln [survival] ) versus the ln of survival time was performed separately for each variable. In the second step, Schoenfeld residuals-based tests were performed for each variable that entered the model, with adjustment for other covariates and for the model as a whole. 12 Next, the patients were divided into 3 groups according to the number of unfavorable factors present for each patient.
Internal validation was performed using 2 bootstrap methods. 13 Bootstrap samples were produced by taking samples from the original data set using random sampling with replacement. In the first method, 500 new data sets were created and entered using the same modelling process used to derive the final model from the original data set. The factors that appeared in > 40% of the computed models were considered significant. In the second method, another 500 bootstrap samples were generated, and Cox regression analysis was repeated for each sample, using the variables selected in the final model. Parameter estimates, hazard ratios, 95% CIs, and P values were produced and compared with those from the model derived from the original data set. The factors achieving P < .05 in this bootstrapping procedure were considered significant. Discrimination is a measure of a model's ability to separate patients with different outcomes. To assess it, the concordance index (c-index) and bias-corrected c-index for protecting against overfitting during stepwise regression were calculated, with the resulting values ranging from 0.5, representing no predictive ability, to 1, representing perfect predictive ability to separate patients.
14 P values less than the a level of .05 (2-sided) were considered significant for all analyses. Cases with missing data for any variable were excluded from the analyses that involved that variable. Statistica, version 10 (StatSoft, Inc.) and R, version 3.2.2 (The R Foundation for Statistical Computing) with the rms package (available at: https://cran.r-project.org/web/packages/rms/index. html) were used to perform the statistical analyses.
Results
Outcomes
A total of 266 patients were enrolled in the present study. Detailed characteristics are listed in Table 1 . Of these patients, 201, 45, and 20 had received sunitinib, pazopanib, and sorafenib,
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Model Building
We found that 22 factors significantly influenced survival when assessed on univariable analysis ( Table 2 ). The median OS differed among the treatment groups (24.8, 17.0, and 38.7 months for sunitinib, pazopanib, and sorafenib, respectively); however, statistical significance was not reached (P ¼ .142). OS was not affected by the use of previous immunotherapy (P ¼ .697).
On multivariable analysis, 6 factors were independently associated with poor survival: Eastern Cooperative Oncology Group PS > 0 (P < .0001), Fuhrman grade 3 to 4 (P < .0001), hemoglobin level less than the lower limit of normal (P < .0001), LDH level greater than the upper limit of normal (P ¼ .0011), NLR ! 4 (P < .0001), and > 2 metastatic sites (P ¼ .0012; Table 3 ). The proportionality of hazards assumption was met for each variable and for the whole model (Table 4) . Fuhrman Grade and NLR in MRCC 
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After constructing the final model, the patients were divided into 3 risk categories according to number of negative prognostic factors for each patient. Patients with no factors were included in the favorablerisk group (n ¼ 26; 11.4%) in which the median OS was not reached. Patients with 1 or 2 factors were included in the intermediate-risk group (n ¼ 115; 50.4%), with a median OS of 35.9 months (95% CI, 27.9-43.9 months). Finally, patients with 3 to 6 factors were included in the poor-risk group (n ¼ 87; 38.2%), with median OS of 8.8 months (95% CI, 5.6-12.0 months). The KaplanMeier curves for each of the 3 risk groups are shown in Figure 2 .
Model Validation
Both bootstrap methods confirmed the appropriate construction of the final model. In the first method, the factors derived from the final model appeared in > 40% of the 500 computed models. In the second method, repeating Cox regression analysis on another 500 random samples entering the factors from the final model resulted in statistical significance for each factor, with almost identical values for the parameter estimates, hazard ratios, and 95% CIs. The discrimination ability was highly satisfactory with a c-index and bias-corrected c-index of 0.759 (95% CI, 0.706-0.812) and 0.751, respectively (Table 4) .
Discussion
TKIs have tremendously changed the perspective for patients with metastatic RCC. The use of prognostic factors can help clinicians determine the appropriate use of these types of drugs by selecting the patients most likely to benefit from them. The present study was conducted to discover whether the performance of the current prognostic tools can be improved.
A general consensus has been reached that the PS remains one of the most significant prognostic factors in RCC. [3] [4] [5] [6] 15 This has been further strengthened by the identical conclusion from the present study. The number of metastatic sites was reported in published studies as a criterion in prognostic models. 5, 6 Similarly, the present study found that involvement of metastatic processes in > 2 sites was independently associated with a poor prognosis. However, the presence of pancreatic metastases increased the median OS by twofold on univariable analysis. This is another indication that pancreatic metastases in RCC might be linked to a less aggressive tumor phenotype. 16 Other frequently reported risk factors, such as the time from diagnosis to therapy initiation and the laboratory test findings, also appeared in our study. However, only anemia and elevated LDH were independently associated with a worse prognosis. The NLR and PLR were also assessed as additional markers of inflammatory response, which had been reported to have an impact on survival in patients treated with TKIs for metastatic RCC. [17] [18] [19] On univariable analysis, an NLR of ! 3 and NLR of ! 4 and a PLR of ! 150 and PLR of ! 200 were more significant factors than the presence of neutrophilia and thrombocytosis, respectively. Of these factors, an NLR of ! 4 appeared in the final model, suggesting it might be even more relevant than neutrophilia; it is also a low-cost and widely available prognostic biomarker. The Fuhrman (nuclear) grade has been recognized as an independent prognostic factor for all-stage and metastatic RCC. 15, 20 In the present study, higher Fuhrman grades (3-4) were strongly associated with a poor outcome. This finding underlines the necessity for further investigations on the relationship between tumor biology and patient survival. The T stage of the TNM classification remains an important factor for the entire population of patients with RCC 15 ; however, it seems to lose significance after the development of metastases. The overrepresentation of patients with clear cell histologic features in our study cohort made it impossible to demonstrate whether the histologic subtype might affect survival. The presence of sarcomatoid features is commonly believed to worsen survival. 21 However, this pathologic feature was rarely observed; therefore, its negative effect might only be shown on univariable analysis. The present study's generated model was sufficiently validated by 2 bootstrap procedures and a bias-corrected c-index of 0.751, notably one of the highest reported in published studies on this subject. However, the limitations of the present study included its retrospective design, the restriction to a single center, and incomplete data collection. Moreover, a selection bias was observed because we excluded patients without previous nephrectomy or nephron-sparing surgery, favoring those with a better PS and generally indicating our population was more fit. The median OS for the whole cohort was greater than the median survival reported in larger population studies. 22, 23 However, 50.4% of patients were in the intermediate-risk group and only 11.4% in the favorable-risk group. The median OS for the poor-risk group was within the range observed in previous, large cohort studies, although the median OS for the intermediate-risk group was longer. This observation can be explained by the Will Rogers phenomenon. 24 Despite these disadvantages, our results are coherent with those from previous reports. Of the 6 factors that emerged in the final model, 4 are frequently recognized as independent criteria for survival: PS, hemoglobin level, LDH level, and the number of metastatic sites. In contrast, the remaining 2-Fuhrman grade and NLR-have yet to be strictly analyzed in the construction of the currently used prognostic models.
Conclusion
In summary, patients with metastatic RCC treated with first-line TKIs possess similar prognostic factors as previously reported in the era of molecular targeted therapies. However, the results of our study have shown that the Fuhrman grade and NLR should be included when predicting patient survival. The model we have proposed presents with satisfactory performance and potential but requires external validation on a larger cohort of patients.
Clinical Practice Points
Many studies have reported on models for predicting the survival of patients with metastatic RCC treated with molecular targeted therapies, including TKIs; however, the number of features investigated by these studies has been limited. The present study reports a prognostic model that consists of 6 factors independently associated with survival. Four (PS, hemoglobin, LDH, and the number of metastatic sites) have been previously recognized as criteria for survival, and 2 (Fuhrman grade and NLR) have yet to be strictly analyzed in the construction of currently used prognostic models. Including the Fuhrman grade and NLR in the prognosis of survival for patients with metastatic RCC could improve the selection of patients most likely to benefit from first-line TKI therapy.
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